LIFE - aTyr Pharma, Inc.
0.4300 +0.01 (2.38%)
After hours: 4:53PM EST
| Previous Close | 0.4259 |
| Open | 0.4300 |
| Bid | 0.4160 x 1000 |
| Ask | 0.4595 x 1000 |
| Day's Range | 0.4200 - 0.4398 |
| 52 Week Range | 0.4200 - 4.2240 |
| Volume | 273,215 |
| Avg. Volume | 468,882 |
| Market Cap | 12.61M |
| Beta (3Y Monthly) | 2.54 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3300 |
| Earnings Date | Aug 13, 2018 - Aug 17, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 1.18 |
- GlobeNewswire•15 days ago
aTyr Pharma Announces Initiation of Phase 1b/2a Study of ATYR1923 in Patients with Pulmonary Sarcoidosis and Collaboration with the Foundation for Sarcoidosis Research (FSR)
SAN DIEGO, Dec. 04, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the initiation of a Phase 1b/2a study evaluating its lead candidate, ATYR1923, in patients with pulmonary sarcoidosis following acceptance of the Company’s investigational new drug application by the US Food and Drug Administration. Under the terms of the collaboration, FSR will assist with clinical trial site initiation and patient enrollment.
- Zacks•20 days ago
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
Zacks.com highlights: Asbury Automotive, OncoGenex Pharmaceuticals, aTyr Pharma, Avinger and Sunesis Pharmaceuticals
- GlobeNewswire•20 days ago
aTyr Pharma to Present at the BMO 2018 Prescriptions for Success Healthcare Conference
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay Shukla, M.D., M.S., president and chief executive officer, will present at the upcoming BMO 2018 Prescriptions for Success Healthcare Conference at the Mandarin Oriental in New York City on Wednesday, December 12, 2018, at 2:30 pm Eastern Time.
- Zacks•21 days ago
5 Top-Ranked Rising P/E Stocks to Lure Investors
Inside the top-ranked stocks that have been exhibiting rising P/E ratios.
- GlobeNewswire•28 days ago
Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Associated Press•last month
Atyr Pharma: 3Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 24 cents. In the final minutes of trading on Tuesday, the company's shares hit 55 cents. A year ago, they were trading at $3.65. ...
- GlobeNewswire•last month
aTyr Pharma Announces Third Quarter 2018 Operating Results and Provides Corporate Update
- Initiation of Proof-of-Concept Study in Patients with Pulmonary Sarcoidosis Planned for Fourth Quarter of 2018 - - Conference Call Today at 5:00 p.m. ET / 2:00.
- GlobeNewswire•last month
aTyr Pharma to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 13, 2018
SAN DIEGO, Nov. 08, 2018 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
- GlobeNewswire•2 months ago
aTyr Pharma Presents at American Society of Human Genetics 2018 Meeting
SAN DIEGO, Oct. 17, 2018 -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel.
- GlobeNewswire•2 months ago
aTyr Pharma Announces Leadership Transition
SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced the resignation of David J. King, Ph.D. as Chief Scientific Officer of aTyr, effective as of December 31, 2018. Dr. King will be pursuing an opportunity as a founder of a private biotechnology company in a non-competitive area and in biology distinct from aTyr. Through the end of the year, Dr. King will assist in transition activities and recruitment of new leadership to continue aTyr’s research efforts.
- GlobeNewswire•3 months ago
aTyr Pharma Announces Pulmonary Sarcoidosis as Disease Indication for Phase 1b/2a Clinical Study and Educational Webinar
SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it has selected pulmonary sarcoidosis as the disease indication for its upcoming ATYR1923 clinical study. In the fourth quarter of 2018, aTyr plans to initiate a Phase 1b/2a multiple-ascending dose, placebo-controlled, first-in-patient study with ATYR1923 for the treatment of patients with pulmonary sarcoidosis. The study has been designed to evaluate safety, tolerability and immunogenicity of multiple doses of ATYR1923. In addition, aTyr intends to evaluate established clinical endpoints and potential biomarkers to assess preliminary activity of ATYR1923. From San Antonio, the site of the CHEST Annual Meeting 2018, aTyr will host an educational webinar on Monday, October 8, 2018 at 8:00 a.m. Eastern Time featuring Daniel Culver, D.O., Director of the Interstitial Lung Disease Program at the Cleveland Clinic. Dr. Culver is also the President-elect of the World Association of Sarcoidosis and Other Granulomatous Disorders and the Chair of the Scientific Advisory Board for the Foundation for Sarcoidosis Research. During the educational webinar, Dr. Culver will provide disease education on pulmonary sarcoidosis and its impact on patients.
- GlobeNewswire•3 months ago
aTyr Pharma to Present at the Cantor Fitzgerald 2018 Global Healthcare Conference
SAN DIEGO, Sept. 20, 2018-- aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that Sanjay ...
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of LIFE earnings conference call or presentation 14-Aug-18 9:00pm GMT
Q2 2018 aTyr Pharma Inc Earnings Call
- Associated Press•4 months ago
Atyr Pharma: 2Q Earnings Snapshot
On a per-share basis, the San Diego-based company said it had a loss of 35 cents. In the final minutes of trading on Tuesday, the company's shares hit 66 cents. A year ago, they were trading at $3.25. ...
- ACCESSWIRE•4 months ago
aTyr Pharma, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / aTyr Pharma, Inc. (NASDAQ: LIFE ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 5:00 PM Eastern Time. ...
- Thomson Reuters StreetEvents•6 months ago
Edited Transcript of LIFE earnings conference call or presentation 19-Mar-18 9:00pm GMT
Q4 2017 aTyr Pharma Inc Earnings Call
- Thomson Reuters StreetEvents•7 months ago
Edited Transcript of LIFE earnings conference call or presentation 14-May-18 12:00pm GMT
Q1 2018 aTyr Pharma Inc Earnings Call
